Use of cannabinoids in the treatment of epilepsy
AssigneeGW Research Limited
InventorsGeoffrey Guy, Stephen Wright, Orrin Devinsky
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of cannabidiol (CBD) in the treatment of focal seizures. In one embodiment the patients suffering from focal seizures are children and young adults. CBD appears particularly effective in reducing focal seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; CDKL5; Neuronal ceroid lipofuscinoses (NCL); febrile infection related epilepsy syndrome (FIRES); Aicardi syndrome and brain abnormalities in comparison to other seizure types. Significantly CBD additionally is very effective in the reduction of a sub-type of focal seizures, focal seizures with impairment.
Claims24
A method of treating focal seizures in Dravet Syndrome, comprising administering to a subject in need thereof cannabidiol (CBD), wherein the CBD has a purity of at least 98% (w/w) and comprises no more than 0.15% (w/w) Δ9-tetrahydrocannabidiol, wherein the CBD is administered at a dose of from 15 mg/kg/day to 20 mg/kg/day.
A method of treating focal seizures in Dravet Syndrome, comprising administering to a subject in need thereof cannabidiol (CBD), wherein the CBD has a purity of at least 98% (w/w) and comprises no more than 0.15% (w/w) Δ9-tetrahydrocannabidiol, wherein the CBD is administered at a dose of 20 mg/kg/day.
Dependencies are inferred from the claim text.